I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
Zacks Investment Research on MSN
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
AbbVie ABBV remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster ...
A new serial-killer documentary has just hit Netflix. But this time the focus is not on one of America’s most notorious murderers — but rather on his daughter. The new doc from director Skye Borgman, ...
Alert EMA Backs COVID Booster for LP.8.1, Expands to Teens The protein-based vaccine now covers the LP.8.1 variant and can be given to adolescents aged 12 years or older who previously received mRNA ...
The Senate for a tenth time Thursday rejected a GOP-backed measure to reopen the government, blocking the funding bill from moving forward with no new supporters, indicating negotiations remain at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback